hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

9. 21. 65

Attorney Docket No.: 02558P-001340US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 1694

James Blake et al.

Examiner: Emily M. Le

Application No.: 09/733,239

Art Unit: 1648

Filed: December 8, 2000

For: CYSTEINE T

CYSTEINE THIOL-PROTECTED

PEPTIDES FOR USE IN IMMUNOASSAYS

DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

SUPPLEMENTAL INFORMATION

Customer No.: 20350

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The reference cited on attached form PTO/SB/08B is being called to the attention of the Examiner. A copy of the reference is enclosed.

The reference was previously submitted in the Information Disclosure Statement filed on August 29, 2001, but not considered on the merits. An English translation of the reference is not available, however, the highlighted portions on page 86 (Diagram 5), page 88

James Blake et al.

Application No.: 09/733,239

Page 2

(Diagram 7), and page 95 (English Summary) are either in English or show peptide synthetic

schematics that use internationally recognized symbols and abbreviations.

It is therefore respectfully requested that the cited reference, particularly the

above-specified sections, be expressly considered during the prosecution of this application, and

the reference be made of record therein and appear among the "references cited" on any patent to

issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the

information and reference cited is prior art merely because it is in this statement and no

representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit

any overpayment to, the above-noted Deposit Account.

Respectfully submitted.

Nicholas V. Sherbina

Reg. No. 54,443

TOWNSEND and TOWNSEND and CREW LLP


Two Embarcadero Center, Eighth Floor

San Francisco, California 94111-3834

Tel: 206-467-9600 Fax: 206-623-6793

NVS:mmm 60585316 v1

PTO/SB/08B (08-03)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 09/733,239 Filing Date December 8, 2000 First Named Inventor James Blake Art Unit 1648 Emily M. Le Examiner Name Attorney Docket Number 02558P-001340US

(use as many sheets as necessary)

Sheet

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Examiner T² Initials * No.1 ST. GUTTMANN, "Synthèse du glutathion et de l'oxytocine à l'aide d'un nouveau groupe protecteur de la fonction thiol," Helv. Chim. Acta, 49:83-96 at pp. 86 AA (Diagram 5), 88 (Diagram 7) and 95 (English Summary) (1966).

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.